Lorrain Daniel S. 4
4 · Contineum Therapeutics, Inc. · Filed Jun 1, 2026
Research Summary
AI-generated summary of this filing
Contineum (CTNM) CSO Daniel S. Lorrain Sells 4,170 Shares
What Happened
Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics, sold 4,170 shares on June 1, 2026. The shares were disposed for a weighted average price of $13.16 per share, totaling approximately $54,862. The sale was reported as an open-market or private sale (code S).
Key Details
- Transaction date: 2026-06-01 (filed the same day).
- Price: weighted average $13.16; individual sale prices ranged from $12.995 to $13.360 (report notes multiple transactions).
- Total proceeds: ~$54,862.
- Shares owned after the transaction: not specified in the filing.
- Footnotes of note:
- F1: Transactions effected pursuant to a 10b5-1 trading plan adopted Sept 23, 2025.
- F2: Price is a weighted average; reporting person will provide breakdown on request.
- F3: Ownership figures in the filing (where shown) include 3,268 shares purchased via the company ESPP on May 15, 2026.
- Filing timeliness: filing date equals transaction date (no late filing indicated).
Context
This was a sale executed under a pre-established 10b5-1 plan, which typically schedules trades in advance and can indicate routine disposition rather than new CEO insider timing. For retail investors, purchases often carry clearer signals about insider conviction; sales can be routine or for personal reasons. If you want exact per-trade details or current insider holdings, the filer offers to provide a breakdown of the individual sale prices on request.
Insider Transaction Report
- Sale
Class A Common Stock
[F1][F2]2026-06-01$13.16/sh−4,170$54,862→ 139,372 total
- 10,110(indirect: By Spouse)
Class A Common Stock
[F3]
Footnotes (3)
- [F1]These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.995 to $13.360, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- [F3]Includes 3,268 shares purchased through Issuer's Employee Stock Purchase Plan on May 15, 2026.